Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: Clinical and endocrine effects
- 31 May 1996
- journal article
- clinical trial
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 32 (5), 789-792
- https://doi.org/10.1016/0959-8049(95)00623-0
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancerBritish Journal of Cancer, 1994
- The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patientsEuropean Journal Of Cancer, 1992
- The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancerBritish Journal of Cancer, 1992
- Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study.Journal of Clinical Oncology, 1990
- Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimideBritish Journal of Cancer, 1989
- 4-HYDROXYANDROSTENEDIONE IN TREATMENT OF POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST CANCERThe Lancet, 1984
- Treatment of Breast Carcinoma with AminoglutethimideActa Radiologica: Oncology, 1984
- EFFECTS OF AMINOGLUTETHIMIDE ON ADRENAL STEROID SECRETIONClinical Endocrinology, 1983
- Aminoglutethimide: a ‘side-effect’ turned to therapeutic advantagePostgraduate Medical Journal, 1970
- Aminoglutethimide (Elipten-Ciba) as an Inhibitor of Adrenal Steroidogenesis: Mechanism of Action and Therapeutic TrialJournal of Clinical Endocrinology & Metabolism, 1967